Effect of CD40 ligand and other immunomodulators on Pneumocystis carinii infection in rat model

Helieh S. Oz; Walter T. Hughes; Jerold E. Rehg; Elaine K. Thomas

doi:10.1006/mpat.2000.0374

Effect of CD40 ligand and other immunomodulators on Pneumocystis carinii infection in rat model

Helieh S. Oz, Walter T. Hughes, Jerold E. Rehg, Elaine K. Thomas

School of Medicine

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

The corticosteroid-treated animal is well established as an experimental model for the study of Pneumocystis carinii pneumonitis (PCP). Latent or acquired infection with P. carinii in the murine lung progresses to fatal pneumonitis when the host is profoundly immunocompromized. In this study the effects of five immunomodulators; recombinant CD40 ligand (CD40L), bryostatin 1, recombinant FLT3 ligand (FLT3L), recombinant granulocyte colony-stimulating factor (G-CSF) and recombinant interleukin-15 (IL-15) were investigated against PCP in a dexamethasone immuno-suppressed Sprague-Dawley rat model. The majority of rats (70%) treated with CD40L at the onset of dexamethasone immunosuppression were protected against PCP. When CD40L was given after 10 days of immunosuppression, only 40% of the rats resolved the infection. However, 95% of the control animals developed PCP. Immunosuppressed rats treated with bryostatin 1, an immune activator had a partial (50%) protection against P. carinii infection. In contrast, daily administration of FLT3L, IL-15 or G-CSF provided no protection against P. carinii infection. (C) 2000 Academic Press.

Original language	English (US)
Pages (from-to)	187-190
Number of pages	4
Journal	Microbial Pathogenesis
Volume	29
Issue number	3
DOIs	https://doi.org/10.1006/mpat.2000.0374
State	Published - 2000

Keywords

Bryostatin 1
CD40L
FLT3L
IL-15
P. carinii
PCP

ASJC Scopus subject areas

Microbiology
Infectious Diseases

Access to Document

10.1006/mpat.2000.0374

Cite this

@article{05debb809c684d2d88ea8212e1580623,

title = "Effect of CD40 ligand and other immunomodulators on Pneumocystis carinii infection in rat model",

abstract = "The corticosteroid-treated animal is well established as an experimental model for the study of Pneumocystis carinii pneumonitis (PCP). Latent or acquired infection with P. carinii in the murine lung progresses to fatal pneumonitis when the host is profoundly immunocompromized. In this study the effects of five immunomodulators; recombinant CD40 ligand (CD40L), bryostatin 1, recombinant FLT3 ligand (FLT3L), recombinant granulocyte colony-stimulating factor (G-CSF) and recombinant interleukin-15 (IL-15) were investigated against PCP in a dexamethasone immuno-suppressed Sprague-Dawley rat model. The majority of rats (70%) treated with CD40L at the onset of dexamethasone immunosuppression were protected against PCP. When CD40L was given after 10 days of immunosuppression, only 40% of the rats resolved the infection. However, 95% of the control animals developed PCP. Immunosuppressed rats treated with bryostatin 1, an immune activator had a partial (50%) protection against P. carinii infection. In contrast, daily administration of FLT3L, IL-15 or G-CSF provided no protection against P. carinii infection. (C) 2000 Academic Press.",

keywords = "Bryostatin 1, CD40L, FLT3L, IL-15, P. carinii, PCP",

author = "Oz, {Helieh S.} and Hughes, {Walter T.} and Rehg, {Jerold E.} and Thomas, {Elaine K.}",

note = "Funding Information: This study was supported in part by the National Cancer Institute Cancer Center Support (Core) Grant P30CA21765, the American Lebanese Syrian Associated Charities and Immunex Corporation.",

year = "2000",

doi = "10.1006/mpat.2000.0374",

language = "English (US)",

volume = "29",

pages = "187--190",

journal = "Microbial Pathogenesis",

issn = "0882-4010",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - Effect of CD40 ligand and other immunomodulators on Pneumocystis carinii infection in rat model

AU - Oz, Helieh S.

AU - Hughes, Walter T.

AU - Rehg, Jerold E.

AU - Thomas, Elaine K.

N1 - Funding Information: This study was supported in part by the National Cancer Institute Cancer Center Support (Core) Grant P30CA21765, the American Lebanese Syrian Associated Charities and Immunex Corporation.

PY - 2000

Y1 - 2000

N2 - The corticosteroid-treated animal is well established as an experimental model for the study of Pneumocystis carinii pneumonitis (PCP). Latent or acquired infection with P. carinii in the murine lung progresses to fatal pneumonitis when the host is profoundly immunocompromized. In this study the effects of five immunomodulators; recombinant CD40 ligand (CD40L), bryostatin 1, recombinant FLT3 ligand (FLT3L), recombinant granulocyte colony-stimulating factor (G-CSF) and recombinant interleukin-15 (IL-15) were investigated against PCP in a dexamethasone immuno-suppressed Sprague-Dawley rat model. The majority of rats (70%) treated with CD40L at the onset of dexamethasone immunosuppression were protected against PCP. When CD40L was given after 10 days of immunosuppression, only 40% of the rats resolved the infection. However, 95% of the control animals developed PCP. Immunosuppressed rats treated with bryostatin 1, an immune activator had a partial (50%) protection against P. carinii infection. In contrast, daily administration of FLT3L, IL-15 or G-CSF provided no protection against P. carinii infection. (C) 2000 Academic Press.

AB - The corticosteroid-treated animal is well established as an experimental model for the study of Pneumocystis carinii pneumonitis (PCP). Latent or acquired infection with P. carinii in the murine lung progresses to fatal pneumonitis when the host is profoundly immunocompromized. In this study the effects of five immunomodulators; recombinant CD40 ligand (CD40L), bryostatin 1, recombinant FLT3 ligand (FLT3L), recombinant granulocyte colony-stimulating factor (G-CSF) and recombinant interleukin-15 (IL-15) were investigated against PCP in a dexamethasone immuno-suppressed Sprague-Dawley rat model. The majority of rats (70%) treated with CD40L at the onset of dexamethasone immunosuppression were protected against PCP. When CD40L was given after 10 days of immunosuppression, only 40% of the rats resolved the infection. However, 95% of the control animals developed PCP. Immunosuppressed rats treated with bryostatin 1, an immune activator had a partial (50%) protection against P. carinii infection. In contrast, daily administration of FLT3L, IL-15 or G-CSF provided no protection against P. carinii infection. (C) 2000 Academic Press.

KW - Bryostatin 1

KW - CD40L

KW - FLT3L

KW - IL-15

KW - P. carinii

KW - PCP

UR - http://www.scopus.com/inward/record.url?scp=0033834761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033834761&partnerID=8YFLogxK

U2 - 10.1006/mpat.2000.0374

DO - 10.1006/mpat.2000.0374

M3 - Article

C2 - 10968950

AN - SCOPUS:0033834761

SN - 0882-4010

VL - 29

SP - 187

EP - 190

JO - Microbial Pathogenesis

JF - Microbial Pathogenesis

IS - 3

ER -

Effect of CD40 ligand and other immunomodulators on Pneumocystis carinii infection in rat model

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this